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Abstract: Several antipsychotics and antidepressants have been associated with QTc prolongation or other electrocardiogram
(ECG) alterations, but their impact is still debated and other risk factors are known to affect QTc. We investigated the effect of
antidepressants and antipsychotics on QTc and other ECG intervals/waves in three samples. Two discovery samples (cross-sec-
tional sample n = 145 and prospective sample n = 68, naturalistic treatment) and a replication prospective sample (Clinical
Antipsychotic Trials of Intervention Effectiveness, n = 515, randomized treatment) were analysed. In both prospective samples,
baseline/follow-up changes in ECG parameters were analysed in relation to the number of psychotropic drugs stratified according
to their known cardiovascular risk. In the cross-sectional sample, ECG parameters were compared among drugs with different
risk profile. The possible effect of single nucleotide polymorphisms (SNPs) in the CACNA1C gene on QTc was also investi-
gated. There was no evidence of mean QTc prolongation or increased risk of clinically relevant QTc prolongation (≥20 msec.) in
association with psychotropic drugs stratified according to their known cardiovascular risk. The prescription of drugs with cardio-
vascular risk was less common in older individuals or individuals with cardiovascular comorbidities. Other factors (gender, base-
line QTc, renal function) affected QTc. rs1006737 and SNPs in linkage disequilibrium with it modulated QTc duration/changes
in all samples. An association between risk drugs and shorter RR interval or higher heart rate was found in all samples. A rele-
vant effect of psychotropic drugs with cardiovascular risk on QTc duration was not observed. A number of factors other than
psychotropic drugs may influence QTc. CACNA1C rs1006737 may modulate QTc in patients treated with psychotropic drugs.
A number of electrocardiogram (ECG) alterations have been
associated with psychotropic drugs, but the most clinically rel-
evant is QTc prolongation (i.e. prolongation of the interval
representing electrical depolarization and repolarization of the
ventricles). Indeed, QTc prolongation is a risk factor for seri-
ous adverse events, including torsade de pointes (TdP), a
potential fatal cardiac arrhythmia [1]. Some antidepressant
drugs (e.g. tricyclic antidepressants (TCAs) and citalopram
[2]) and most antipsychotics have a potential to prolong QTc
interval by inhibiting cardiac Na+, Ca2+ and/or K+ channels
[3].
The most recent meta-analysis investigating the effects of
antidepressant drugs on QTc showed that selective serotonin
reuptake inhibitors (SSRIs) and TCAs appear to cause QTc
prolongation by about 6 and 13 msec., respectively, as com-
pared to placebo [2]. According to this meta-analysis, citalo-
pram, escitalopram and sertraline were associated with greater
prolongation than placebo, while fluoxetine and paroxetine
were not. These results are based on randomized controlled
trials (RTCs). Among antipsychotics, those associated with
more QTc prolongation are sertindole, amisulpride, ziprasi-
done, iloperidone and risperidone (in decreasing order) [4].
Haloperidol has been associated with lower mean QTc prolon-
gation, but cases of TdP and sudden death during treatment
with haloperidol therapeutic doses have been reported [5].
Medications are not the only factors affecting QTc duration
(and consequently TdP risk), as non-pharmacological variables
are known to influence them, including gender, age, genetic
factors, electrolyte disturbances, endocrine, metabolic and car-
diovascular diseases [6–9]. Thus, the systematic evaluation of
these factors is expected to be more effective in the prevention
of arrhythmic events than the simple evaluation of QTc and/or
of pharmacological risk factors. In recent years, several warn-
ings were issued by regulatory authorities on the risk of ECG
abnormalities among individuals exposed to psychotropic
drugs. Nevertheless, there is the possibility that, in some cases,
the risk of clinically significant QTc prolongation associated
with psychotropic drugs has been overestimated. For example,
the citalopram study that prompted safety warnings by regula-
tory authorities did not measure the proportion of individuals
with QTc above a certain threshold, but it only reported a
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mean QTc change from baseline to follow-up of 8.5 msec.
with citalopram 20 mg/day, and 18.5 msec. with citalopram
60 mg/day [10]. No cases of citalopram-induced sudden car-
diac death were reported among patients taking up to 60 mg/
day of citalopram and free of risk factors for QTc prolonga-
tion and TdP [11]. Thus, it should be noted that a threshold of
5 msec. (as mean prolongation value) is generally used as the
minimal difference for significance in population studies [5],
but medications that prolong the mean QTc interval by more
than 20 msec. are associated with increased risk of TdP (US
Department of Health and Human Services). In terms of abso-
lute QTc interval duration, values more than 500 msec. are
considered at risk of TdP and this threshold has been sug-
gested for drug discontinuation. A QTc of <450 msec. and
470 msec. for men and women, respectively, is generally
deemed safe by most cardiologists as the cut-off before any
intervention [5].
In addition to QTc interval prolongation, the use of antide-
pressant and antipsychotic drugs has been associated with sev-
eral other ECG alterations, including QRS (that corresponds to
the depolarization of the right and left ventricles) [12] and PR
(the period that extends from the onset of atrial depolarization
to the onset of ventricular depolarization) interval changes
[13], heart rate modification [14,15] and morphological alter-
ations of T and P waves [16,17]. These alterations have been
much less studied than effects on QTc interval and they do
not have established clinical significance.
As described, the prevalence and degree of QTc prolonga-
tion associated with psychotropic drugs are still debated. This
study aimed to investigate changes in QTc duration in patients
treated with antidepressants and/or antipsychotics to improve
the current knowledge on the topic. Further, we evaluated
whether other clinical factors and genetic polymorphisms in
the CACNA1C (calcium channel, voltage-dependent, L-type,
alpha-1C subunit) gene may be associated with QTc changes.
It encodes for the ion permeating subunit of the alpha-1 sub-
unit of cardiac L-type calcium channel (LTCC), which deter-
mines the main biophysical and pharmacological properties of
the channel. The other reason for studying polymorphisms in
this gene was that genetic variants of CACNA1C were associ-
ated with arrhythmic diseases (long QT syndrome and Bru-
gada syndrome) [18]. Finally, CACNA1C has been also
associated with different psychiatric disorders [19]; thus, vari-
ants in this gene are expected to show higher frequency in
individuals with psychiatric disorders than in the general pop-
ulation. The possible association between psychotropic drugs




Original samples. Samples were recruited among inpatients admitted
at ‘Ospedale Maggiore’ in Bologna and outpatients under psychiatric
care at ‘Centri Ansia-Umore’ of Bologna University. The inclusion
criteria were as follows: (i) diagnosis of mood or psychotic disorder
according to DSM-IV-R criteria; (ii) clinical indication for treatment
with an antidepressant and/or antipsychotic drug; (iii) availability of at
least one standard ECG recording; (vi) absence of unstable or severe
medical conditions (e.g. recent acute myocardial infarction, acute or
severe organ failure, cancer or severe chronic diseases); (v) absence of
cognitive impairment or other conditions that would interfere with the
ability to provide a valid informed consent; and (vi) pregnancy or
breastfeeding. Polytherapy with psychotropic drugs or concomitant
treatments for general medical conditions were not exclusion criteria,
but they were considered in the analyses (see paragraph Statistical
analysis and Data S1).
At the time of study entry, demographic characteristics, psychiatric
and general medical diagnosis and current pharmacological treatments
were recorded. A standard 12-lead ECG was prescribed to all patients
at baseline as well as blood tests (including blood count, creatinine,
sodium, potassium, magnesium and calcium plasma levels, transami-
nases). ECG and blood tests were repeated at discharge from hospital
(inpatients) or after a change in treatment. ECG intervals as well as
specific morphological alterations were evaluated independently by
two cardiologists who were blind to genotypes and clinical informa-
tion including drug prescription. Follow-up information was available
in 68 patients (prospective sample). For 145 patients, no follow-up
information was available (outpatients who did not provide the sched-
uled examinations or who had no clinical indications for follow-up
examinations or dropped out from the study), so only baseline data
were available (cross-sectional sample). A representation of the
patients’ selection process is provided in a flow chart in Figure S1.
All patients provided written informed consent after the explanation
of the aims and procedures of the study. The protocol and the written
informed consent were approved by the local ethics committee.
Clinical antipsychotic trials of intervention effectiveness sample. The
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
study was a multi-centre, double-blind study that aimed to evaluate
the relative effectiveness of a first-generation antipsychotic,
perphenazine, compared with several second-generation antipsychotics
(olanzapine, quetiapine, risperidone and ziprasidone), using a
randomized design (phase 1). In phase 2, patients who stopped the
first antipsychotic due to lack of efficacy were randomly assigned to
receive either clozapine or an atypical antipsychotic (olanzapine,
risperidone or quetiapine) different from the one taken in phase 1.
Participants who stopped the first antipsychotic due to side-effects
were randomly assigned to receive either ziprasidone or an atypical
medication different from the phase 1 medication. If the phase 2 study
drug was discontinued, individuals could enter phase 3, in which
clinicians helped individuals to select an open-label treatment based
on individuals’ experiences in phases 1 and 2. Concomitant
medications (including psychotropic drugs) were permitted throughout
the trial, except for additional antipsychotic agents, and this was taken
into account in the analyses (see paragraph Statistical analysis and
Data S1). Further information about CATIE (including inclusion and
exclusion criteria) was reported elsewhere [20] and in Figure S1.
For the purpose of the present study, all the three phases were con-
sidered. Indeed, standard ECG and blood tests (including blood count,
creatinine, sodium, potassium, calcium) were recorded at baseline and
at the end of each phase. For patients who lacked information of inter-
est at the end of phase 1, those recorded at the end of phase 2 or 3
were considered. Using this method, 515 patients had both baseline
and follow-up data referred to ECG and blood tests. A representation
of the patients’ selection process is provided in Figure S1.
Outcome under investigation. The primary outcome was the
evaluation of the effect of psychotropic drugs on QTc interval and its
possible modulation by CACNA1C polymorphisms. This outcome
was investigated through the classification of psychotropic drugs
according to their risk of inducing QTc prolongation (high–moderate
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risk, low risk and no risk according to updated popular guidelines
[21], see Table S1 for an overview). This classification was chosen
because this study primarily aimed to test the applicability of
previously reported pharmacological risk factors for QTc prolongation
across naturalistic clinical settings (i.e. settings reflecting real clinical
practice). QTc was calculated according to Bazett’s formula
(QTc = QT/√RR) [22]). Bazett’s formula is the most popular in
clinical practice, research and education, although its performance is
different as heart rate varies [23]. Several measures of QTc duration
were considered: 1) QTc per cent change between baseline and
follow-up and QTc change ≥20 msec. in the two prospective samples;
and 2) absolute QTc value and QTc >median or >450 msec. in the
cross-sectional sample. QTc change ≥20 msec. and QTc >450 msec.
were chosen because of their clinical significance [21,24]. The
measures described in 1) and 2) were evaluated for association with a)
change in the number of medications with moderate–high risk, low
risk and the total number of medications with cardiovascular risk
between baseline and follow-up in the two prospective samples both
considering the whole sample and only individuals who were drug-
free at baseline; b) the number of medications with moderate–high
risk, low risk and the total number of medications with cardiovascular
risk in the cross-sectional sample; and c) monotherapy (only one drug
with cardiovascular risk) versus polytherapy (combinations of two or
more drugs with cardiovascular risk) in all samples. Indeed,
combination of psychotropic drugs was not an exclusion criterion in
any of the analysed samples, but only in CATIE antipsychotic
combinations were not allowed. The number of drugs with
cardiovascular risk considered for analyses a) and b) was
dichotomized (≤0 and >0).
The secondary outcome of the present study was the evaluation of
the effect of psychotropic drugs on other ECG intervals (PR, QRS, RR
(the interval between successive R waves) and QR (that corresponds to
the first phase of ventricular depolarization)) and morphological alter-
ations of T, ST and R waves. The effect of CACNA1C polymorphisms
was not considered when investigating secondary outcome. Psy-
chotropic drugs were classified according to the criteria described
above. The following measures were considered when we investigated
secondary outcome: (i) per cent change in the reported ECG intervals
in both prospective samples and new observation of a morphological
alteration in the reported waves in the original prospective sample; and
(ii) duration of the reported intervals and observation of morphological
alterations in the cross-sectional sample. The measures described in (i)
and (ii) were evaluated for association with (a) change in number of
medications with moderate–high risk, low risk and change in total
number of medications with cardiovascular risk between baseline and
follow-up in the two prospective samples; and (b) the number of medi-
cations with moderate–high risk, low risk and the total number of med-
ications in the cross-sectional sample. The number of drugs with
cardiovascular risk considered for analyses (a) and (b) was dichoto-
mized as described above.
Single nucleotide polymorphisms selection and genotyping. The
complete list of genotyped polymorphisms and their main
characteristics is reported in Table S2. In the original samples,
genotyping was performed by real-time PCR using Taqman Assay
(Thermo Fisher Scientific, Waltham, MA USA 02451) as
recommended by the manufacturer. Details about single nucleotide
polymorphisms (SNPs) selection and quality control are reported in
Data S1.
In CATIE, 738 participants were genotyped by Perlegen Sciences
using the Affymetrix 500K and Perlegen’s custom 164K chip [25]. As
the SNPs of interest were not available in the original data set, chro-
mosome 12 was imputed using the Haplotype Reference Consortium
(HRC version 1) panel as reference. Standard pre- and post-imputation
quality control was performed and the SNPs of interest were extracted.
Details are provided in Data S1.
Statistical analysis. Associations were investigated using linear or
logistic regression models as appropriate. Covariates were selected for
each outcome considering the impact of possible confounders.
Heterogeneity between patients receiving or not risk drugs was also
taken into account. In CATIE, ancestry-informative principal
components were determined using Eigensoft [26,27] and they were
used as covariates in all genetic analyses to account for different
ancestry components. The use of non-psychotropic medications that
can induce QTc prolongation was also considered. Further details are
reported in Data S1.
In the two original samples, the possible impact of genetic polymor-
phisms on QTc duration or change was investigated as well as the
possible interaction between polymorphisms and risk medications in
determining the investigated phenotypes. In the latter case, a regres-
sion model including an interaction term, calculated as number of
medications with cardiovascular risk (cross-sectional sample) or
change in the number of medications with cardiovascular risk
(prospective samples) 9 genotype, was included. Regression models
included the same covariates used in the clinical analyses. Both domi-
nant and recessive models were investigated.
In CATIE, the same method was applied but only SNPs showing
evidence of association with outcome in at least one original sample
or in linkage disequilibrium (LD) with them (R2 ≥ 0.30) were investi-
gated.
Power and significance threshold. Associations were considered
significant when they were replicated in the same direction in at least
two of the analysed samples with p value < 0.05.
For continuous outcome, considering an alpha value of 0.05, the
present study had a power of 0.80 to identify effect sizes of 0.07, 0.15
and 0.02 in the original cross-sectional, original prospective and
CATIE samples, respectively. For dichotomous outcome, considering
an alpha value of 0.05, the present study had a power of 0.80 to iden-
tify an OR of 1.85, 2.55 and 1.37 in the original cross-sectional, origi-
nal prospective and CATIE samples, respectively. Power estimation
was performed using G*Power 3.1 [28].
Results
The clinical demographic characteristics of the three samples
are reported in Table S3. The variables with an impact on
ECG parameters or that were heterogeneous between patients
who received or not drugs with cardiovascular risk are sum-
marized in Table S4. These variables included gender, age,
GFR (Glomerular Filtration Rate), baseline QTc duration, cal-
cium or magnesium plasma levels, cardiovascular comorbidi-
ties, ethnic group. These variables were used as covariates in
the corresponding regression models.
QTc interval: clinical findings.
No individual had a QTc interval >500 msec., except one
patient from the CATIE study. This was a 43-year-old, White
female who had a baseline QTc = 423 msec.; at follow-up,
she had QTc = 511 msec. and she switched from olanzapine
to ziprasidone, while she did not take other medications with
known cardiovascular risk.
In all the analysed samples, individuals who increased the
number of medications with cardiovascular risk (prospective
samples) or were taking medications with cardiovascular risk
(cross-sectional sample) had no evidence of mean QTc
increase or longer QTc interval, but the opposite was observed
© 2016 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
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(table 1). Indeed, in the original prospective sample, patients
who increased the number of medications with moderate–high
cardiovascular risk had a lower mean QTc per cent change
compared with patients who did not change the number of
medications with moderate–high risk (p = 0.001, Figure S2).
The same association was found in CATIE when considering
the variation in the total number of drugs with cardiovascular
risk (p = 0.01, Figure S2). The same effect was observed
when considering the risk of QTc increase ≥20 msec. in
CATIE (p = 0.02, OR = 0.63, 95% CI = 0.43–0.93; Fig-
ure S3); a similar trend was found in the original prospective
sample (p = 0.07; Figure S3). In the cross-sectional sample,
patients who were not taking drugs with cardiovascular risk
showed higher probability of longer QTc duration than the
median value (380 msec.) compared with patients who were
treated with these drugs (p = 0.03, OR = 0.44, 95%
CI = 0.20–0.93). The same finding was observed when
including only patients who were drug-free at baseline in the
original prospective sample but not in CATIE (Table S5).
When we compared patients treated with combinations of
drugs with cardiovascular risk compared with patients treated
with a single drug (Table S6), we found a trend of longer
QTc duration in patients treated with polytherapies compared
with monotherapy in the cross-sectional sample (p = 0.07).
QTc interval: pharmacogenetic findings.
The SNPs with evidence of association with QTc change or
duration in at least one sample are reported in table 2, while
an overview of all findings is reported in Table S7 for the
original samples and Table S8 for CATIE. rs10848635 and
rs2283326 showed an effect on QTc in both original samples,
but with no consistency in the direction of the effect.
rs1006737 had a consistent effect in the two original samples
(table 2). In the prospective sample, minor homozygotes (AA)
showed lower mean QTc per cent variation than carriers of
the major allele (G) (p = 0.01) between baseline and follow-
up. In addition, AA homozygotes did not show QTc prolonga-
tion when one drug with moderate–high risk was added while
G allele carriers did (p = 0.002; Figure S4). In the cross-sec-
tional sample, AA homozygotes showed lower mean QTc
duration (msec.) than G allele carriers when at least one medi-
cation with moderate–high risk was prescribed (p = 0.045;
Figure S4). In CATIE, four SNPs in LD with rs1006737 were
associated with QTc increase in patients who received the pre-
scription of drugs with cardiovascular risk. The rs1006737 A
allele was found in LD with rs2007044 G allele, rs2239048 A
allele, rs11062188 C allele and rs2239049 G allele, and carri-
ers of these alleles showed a lower QTc per cent increase
when the number of medications with cardiovascular risk was
increased (p = 0.01). These findings are shown in Figure S4.
Interestingly, rs2239048 was also associated with the risk of
QTc prolongation ≥20 msec. in CATIE (E = 1.69,
S.E. = 0.50, z = 3.36, p = 0.0008) and the protective A
allele showed OR = 0.18 (95% CI = 0.07–0.49). rs2007044 G
allele showed a trend of protective effect towards the risk of
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z = 1.74, p = 0.08). The possible interactive effect
rs1006737 9 medications towards the risk of QTc prolonga-
tion ≥20 msec. was not evaluable in the original prospective
sample, due to the small sample size, while there was only a
slight trend of association in the cross-sectional sample
(p = 0.11).
rs2283326 and rs1034936 were associated with QTc in a
consistent way in CATIE and in the original cross-sectional
sample. For both SNPs, minor allele carriers showed a protec-
tive effect (table 2).
Finally, the effect of rs1016388 on QTc was not consistent
between CATIE and the original prospective sample (table 2).
Other ECG intervals.
The most robust finding was the association between the pre-
scription of medications with high–moderate risk and the
decrease in RR interval duration or increase in heart rate that
was found in all samples (Table S9). CATIE patients who
received at least one additional medication with moderate–
high risk compared with baseline had a heart rate increase of
7.82  25.56% compared with baseline value.
No other association was replicated at least in two samples.
An overview of all findings is reported in Table S9.
Discussion
Overview of findings.
In the three analysed samples, no evidence of QTc prolonga-
tion or longer QTc duration was found in patients treated
with psychotropic drugs with previously reported
cardiovascular risk. On the contrary, patients who received
the prescription of at least one additional drug with cardio-
vascular risk compared with baseline showed lower QTc
mean prolongation and lower risk of QTc prolongation
≥20 msec. at follow-up in the prospective original sample
and in CATIE (table 1). In the cross-sectional sample, higher
QTc mean values were found in individuals who were not
treated with drugs with cardiovascular risk, in line with find-
ings in the two prospective samples (table 1). These results
can be explained taking into account other factors affecting
QTc duration. In the original prospective sample, patients
who did not receive the prescription of drugs with moderate–
high cardiovascular risk were older (p = 0.04) and they had
higher prevalence of cardiovascular diseases (p = 0.025).
Non-significant trends in the same direction were found in
the cross-sectional sample while in CATIE, the prescription
of risk drugs was different across ethnic groups (European,
African American and other ethnic groups, p = 0.002) and
Europeans showed higher QTc duration at baseline
(p = 0.03) according to previous findings that supported
interethnic differences in QTc duration [29]. Further, other
non-pharmacological factors were found to modulate QTc
change or duration (gender, baseline QTc duration and renal
function). Only the combination of more than one drug with
cardiovascular risk showed a trend of association with longer
mean QTc duration (p = 0.07 in the cross-sectional sample,
Table S6). We suggest that the lower prescription of psy-
chotropic drugs with cardiovascular risk in individuals with
pre-existing risk factors for QTc prolongation, including the
ones reported above, is partly responsible for the obtained
results, probably in the context of clinicians’ awareness of
Table 2.
Genetic association with p < 0.05 in the prospective original sample (A), cross-sectional sample (B) and CATIE (C).
SNP Genetic model Model Results
(A)
rs10848635 Dominant SNP 9 tot risk meds E = 0.14, S.E. = 0.05, t = 2.59, p = 0.01
rs1006737 Dominant Non-interaction model E = 0.08, S.E. = 0.03, t = 2.65, p = 0.01
SNP 9 mod- to high-risk meds E = 0.19, S.E. = 0.06, t = 3.32, p = 0.0016
rs1016388 Dominant SNP 9 tot risk meds E = 0.16, S.E. = 0.05, t = 3.11, p = 0.003
rs11615998 Recessive Non-interaction model E = 0.12, S.E. = 0.05, t = 2.50, p = 0.02
rs2283326 Recessive Non-interaction model E = 0.05, S.E. = 0.02, t = 2.28, p = 0.03
rs215976 Recessive Non-interaction model E = 0.06, S.E. = 0.02, t = 2.58, p = 0.01
(B)
rs1006737 Dominant SNP 9 mod- to high-risk meds E = 46.63, S.E. = 22.97, t = 2.03, p = 0.045
rs2283326 Dominant SNP 9 low-risk meds E = 59.19, S.E. = 27.01, t = 2.19, p = 0.03
rs10848635 Recessive Non-interaction model E = 15.37, S.E. = 7.53, t = 2.04, p = 0.04
rs11062296 Recessive Non-interaction model E = 21.46, S.E. = 10.01, t = 2.14, p = 0.03
rs1034936 Recessive SNP 9 mod- to high-risk meds E = 29.52, S.E. = 14.44, t = 2.04, p = 0.04
(C)
rs1034936 Dominant SNP 9 tot risk meds E = 2.65e-02, S.E. = 1.30e-02, t = 2.04, p = 0.04
rs2007044 Recessive SNP 9 tot risk meds E = 2.32e-02, S.E. = 1.15e-02, t = 2.02, p = 0.04
rs2239048, rs11062188, rs2239049 Recessive SNP 9 low-risk meds E = 0.03, S.E. = 0.01, t = 2.53, p = 0.01
rs1016388 Recessive SNP 9 tot risk meds E = 2.34e-02, S.E. = 1.10e-02, t = 2.13, p = 0.03
rs2283326 Recessive SNP 9 mod- to high-risk meds E = 3.07e-02, S.E. = 1.11e-02, t = 2.78, p = 0.006
SNP 9 tot risk meds E = 2.57e-02, S.E. = 1.04e-02, t = 2.46, p = 0.01
rs10848677 Recessive SNP 9 mod- to high-risk meds E = 0.02, S.E. = 0.01, t = 2.08, p = 0.038
CATIE, Clinical Antipsychotic Trials of Intervention Effectiveness; SNPs, single nucleotide polymorphisms.
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the cardiovascular risks associated with some psychotropic
drugs. Previous population studies investigating the effect of
antidepressants and antipsychotics on QTc interval duration
are useful to interpret the present findings as they reflect real
clinical practice settings. A longitudinal study including 8222
individuals investigated QTc duration, changes and abnormal
prolongation in association with psychotropic drug use, and
it reported shorter mean QTc duration in users of several
psychotropic drugs previously associated with QTc prolonga-
tion as compared with non-users (e.g. perphenazine and phe-
nothiazines as a group, quetiapine, sulpiride and clozapine
[30]). A cross-sectional population study that included 2411
patients did not find associations between the use of
haloperidol, citalopram or escitalopram in addition to antipsy-
chotic drugs, and QTc prolongation, whereas the use of two
or more antipsychotic drugs was positively associated with
QTc prolongation [31]. The same study reported that only
1% of patients treated with risk psychotropic drugs showed a
QTc >500 msec. and 3% had a QTc exceeding 480 msec.
Another interesting study, examining severe cardiac adverse
drug reactions in 169,278 psychiatric inpatients treated with
antidepressants [32], reported QTc interval prolongation
above 500 msec. in 18 cases (0.01%) associated with TCAs
prescription; alternative explanations for the QTc interval pro-
longation or pre-existing risk factors were suspected in 11
cases. On the other hand, a study based on the examination
of electronic health records of 38,397 patients receiving
antidepressant drugs demonstrated an effect of amitriptyline,
citalopram and escitalopram on QTc interval whereas no
effect of the TCA nortriptyline was observed [33]. Other
similar inconsistencies can be found in naturalistic studies.
For example, a study on a sample of 1006 institutionalized
schizophrenic patients on long-term antipsychotic treatment
found longer QTc intervals in patients treated with clozapine
compared to risperidone and typical antipsychotics; in partic-
ular, risperidone, perphenazine, chlorpromazine and haloperi-
dol had no significant effect on QTc prolongation [34]. The
result was confirmed after correction for cardiovascular dis-
ease, while metabolic alterations, including obesity and dia-
betes, that are associated with clozapine, were not
considered, but they could have influenced the findings [8].
Thus, taking into account the results of previous naturalistic
studies and the present findings, the prevalence of significant
QTc prolongation and severe cardiac adverse events in asso-
ciation with risk psychotropic drugs is probably low. Incon-
sistent findings have been reported about which drugs may
be responsible of QTc prolongation or cardiac adverse
events. Overall, it is known that several demographic and
clinical factors affect QTc duration [8] and they may have
more relevance together in influencing QTc than psychotropic
drugs in real clinical settings.
Genetic factors are also known to affect QTc interval dura-
tion. Candidate gene studies investigated mainly polymor-
phisms in genes coding for ion channels involved in
myocardiocyte depolarization and repolarization, particularly
subunits of potassium channels [35], sodium (SCN5A) ion
channels [36,37] and calcium channels (CACNA1C
[18,38–40]. Other studies were focused on genes coding for
enzymes involved in drug pharmacokinetics (e.g. CYP450
isoenzymes) [41,42] and the nitric oxide synthase 1 adaptor
protein gene (NOS1AP) that affects cardiac repolarization [9].
The present study investigated the association between 13
polymorphisms in the CACNA1C gene and QTc duration;
possible interactions between polymorphisms and prescription
of drugs with cardiovascular risk were considered. rs1006737
A allele was associated with a protective effect towards QTc
prolongation in patients treated with psychotropic drugs with
moderate–high cardiovascular risk in the original perspective
sample. The same allele was associated with lower mean
QTc duration in patients treated with these drugs in the
cross-sectional sample. In CATIE, four alleles in LD with the
rs1006737 A allele (rs2007044 G, rs2239048 A, rs11062188
C and rs2239049 G) were found to have a protective effect
towards QTc prolongation, in line with the findings in the
original prospective sample. The rs1006737 variant is located
in an intronic region, and it has been associated with
increased risk of several psychiatric disorders [19]. Interest-
ingly, recently a case report suggested the hypothesis that this
polymorphism may confer susceptibility to both Brugada syn-
drome and bipolar disorder [43].
In regard to secondary outcome, the present study found an
association between psychotropic drugs with cardiovascular
risk and reduced/shorter RR interval in the two original sam-
ples and higher heart rate in CATIE. Noradrenergic antide-
pressants, inhibiting noradrenaline reuptake, were reported to
increase heart rate [15], an effect that is common to several
psychotropic drugs through different combination of a-adre-
nergic and muscarinic antagonist mechanisms. Indeed, TCAs,
first-generation (e.g. phenothiazines) and second-generation
(e.g. clozapine, olanzapine, quetiapine, risperidone, paliperi-
done) antipsychotics, have been associated with increased
heart rate or tachycardia [44–47]. A growing body of epidemi-
ological and clinical evidence has shown that high resting
heart rate even within the accepted normal range is indepen-
dently associated with increased risk of cardiovascular mortal-
ity and all-mortality causes [48,49]. Thus, high resting heart
rate should not be overlooked in patients treated with psy-
chotropic drugs, particularly because pharmacological heart
rate control can be easily obtained.
Strengths and limitations.
The limitations of the study have to be considered. Firstly, the
limited size of the original samples probably influenced the
power of detecting significant effects. It should be noted that
this was the reason why we used multiple samples (including
CATIE, n = 515) to test our hypotheses. Secondly, samples
were heterogeneous in terms of study design (cross-sectional
and longitudinal) as well as clinical demographic characteris-
tics. On the other hand, this could be seen as strength as find-
ings are expected to be reproducible in different clinical
contexts and reflect a real clinical scenario. Similarly, mild
cardiac diseases such as non-severe cardiac valvulopathies,
mild hypertensive heart disease or past myocardial infarction
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with conserved ventricular function were not considered as
exclusion criteria, and this may be interpreted as a limitation
as well as a reflection of real clinical world. Thirdly, the effect
of single drugs or classes of drugs was not investigated due to
sample size issues. To the best of our knowledge, this is the
first study that investigated ECG alterations in association with
psychotropic drugs classified as having moderate–high, low
and no cardiovascular risk according to previous findings.
This classification may seem a simplification that does not
take into account the different pharmacodynamic profiles of
psychotropic drugs, but it was a strategy to study the cardiac
effects of these drugs in real clinical settings. Thus, this study
was an attempt to verify relatively established research find-
ings (included in clinical guidelines) in real clinical settings.
We had to choose a priori to refer to one classification of psy-
chotropic drugs’ cardiovascular risk, resulting in potential bias;
thus, we decided to refer to widespread clinical guidelines and
not to new and poorly replicated findings. Despite its popular-
ity in clinical practice, research and education, Bazett’s for-
mula shows a different performance depending on heart rate
[23]. Indeed, Bazett’s formula produces higher QTc values
above 60 bpm (beats per minute) compared with other formula
and generally lower values below 60 bpm. Despite this limita-
tion, we decided to use this formula because of its widespread
use and consequently higher comparability of results with
other studies. Interestingly, our results showed lower mean
QTc change or duration in patients who increased the number
of medications with cardiovascular risk, and in this group, an
increase in heart rate was demonstrated. Thus, the lower risk
of QTc prolongation (prospective samples) or shorter QTc
duration (cross-sectional sample) cannot be a consequence of
heart rate variation. Finally, other genetic and non-genetic fac-
tors have probably contributed to the observed changes in
QTc and other ECG variables.
Conclusions
The present study found no evidence of QTc interval prolon-
gation in patients treated with psychotropic drugs with moder-
ate–high or low cardiovascular risk compared with patients
not treated with these drugs. On the contrary, patients who
were not treated with these drugs showed higher QTc mean
prolongation and higher risk of QTc prolongation ≥20 msec.
in the prospective original sample and in CATIE, probably as
a result of non-pharmacological factors (such as age, concomi-
tant cardiovascular diseases and race). These results suggest
that popular classifications of psychotropic drugs’ cardiovascu-
lar risk (that are often based on randomized trials) do not nec-
essarily reflect what is observed in naturalistic clinical
settings. CACNA1C rs1006737 SNP and SNPs in LD with it
may influence the risk of QTc prolongation in patients treated
with psychotropic drugs with cardiovascular risk. The effect of
medications with cardiovascular risk on heart rate was con-
firmed in all the analysed samples, suggesting that a careful
monitoring of heart rate and treatment of high resting heart
rate should be considered.
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